Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima, 734-0037, Japan.
Department of Anatomical Pathology, Hiroshima University Hospital, Hiroshima, Japan.
Breast Cancer Res Treat. 2018 Sep;171(2):315-323. doi: 10.1007/s10549-018-4791-1. Epub 2018 May 19.
Dedicated breast positron emission tomography (DbPET) provides detailed high-resolution images and can detect intratumoral heterogeneity using F-fluorodeoxyglucose (FDG). We aimed to evaluate the correlation between FDG uptake on DbPET and the clinicopathological features of breast cancer, particularly those with an intratumoral heterogeneous distribution of FDG on DbPET.
We evaluated 195 consecutive patients with invasive breast cancer who underwent preoperative whole-body PET (WBPET) and DbPET concurrently between January 2016 and March 2017. The relationships between clinicopathological factors and the maximum standard uptake values (SUVmax) of DbPET and WBPET, including clinical stage, nuclear grade, Ki67 proliferation index, estrogen receptor (ER) and human epidermal growth factor receptor type 2 (HER2) statuses, and the intratumoral heterogeneous distribution of FDG on DbPET, were evaluated.
The SUVmax of DbPET was significantly correlated with clinical T stage, N stage, nuclear grade, and Ki67 proliferation index (all p < 0.001) as well as the ER (p = 0.006) and HER2 (p = 0.040) statuses. Intratumoral heterogeneous distribution of FDG on DbPET was significantly related with high nuclear grade (p = 0.016) and high Ki67 proliferation index (p = 0.015) but not with clinical T stage, N stage, and ER and HER2 statuses.
The SUVmax of DbPET correlates with clinicopathological factors and also WBPET does. In addition, intratumoral heterogeneity on DbPET provides predictive value for malignancy grade and could inform therapeutic decisions.
专用乳腺正电子发射断层扫描（DbPET）提供详细的高分辨率图像，并可使用 F-氟脱氧葡萄糖（FDG）检测肿瘤内异质性。我们旨在评估 DbPET 上 FDG 摄取与乳腺癌临床病理特征之间的相关性，尤其是那些在 DbPET 上存在 FDG 肿瘤内异质性分布的乳腺癌。
我们评估了 2016 年 1 月至 2017 年 3 月期间 195 例连续接受术前全身 PET（WBPET）和 DbPET 的浸润性乳腺癌患者。评估了 DbPET 和 WBPET 的最大标准摄取值（SUVmax）与临床病理因素之间的关系，包括临床分期、核分级、Ki67 增殖指数、雌激素受体（ER）和人表皮生长因子受体 2（HER2）状态以及 DbPET 上 FDG 的肿瘤内异质性分布。
DbPET 的 SUVmax 与临床 T 分期、N 分期、核分级和 Ki67 增殖指数显著相关（均 p<0.001），与 ER（p=0.006）和 HER2 状态（p=0.040）也显著相关。DbPET 上 FDG 的肿瘤内异质性分布与高核分级（p=0.016）和高 Ki67 增殖指数（p=0.015）显著相关，但与临床 T 分期、N 分期以及 ER 和 HER2 状态无关。
DbPET 的 SUVmax 与临床病理因素相关，与 WBPET 也相关。此外，DbPET 上的肿瘤内异质性为恶性程度提供了预测价值，并可指导治疗决策。
